$2.23
0.89% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US00887A1051
Symbol
ALRN
Sector
Industry

Aileron Therapeutics, Inc. Stock price

$2.23
-0.51 18.61% 1M
-0.67 23.10% 6M
-0.82 26.85% YTD
-1.04 31.80% 1Y
-8.65 79.50% 3Y
-10.17 82.02% 5Y
-213.77 98.97% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.02 0.89%
ISIN
US00887A1051
Symbol
ALRN
Sector
Industry

Key metrics

Market capitalization $48.32m
Enterprise Value $75.65m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio 0.96
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-29.62m
Cash position $17.68m
EPS (TTM) EPS $-3.11
P/E forward negative
Short interest 1.08%
Show more

Is Aileron Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Aileron Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Aileron Therapeutics, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Aileron Therapeutics, Inc. forecast:

Buy
100%

Financial data from Aileron Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.12 0.12
9% 9%
-
-0.12 -0.12
9% 9%
-
- Selling and Administrative Expenses 16 16
103% 103%
-
- Research and Development Expense 13 13
192% 192%
-
-30 -30
133% 133%
-
- Depreciation and Amortization 0.12 0.12
9% 9%
-
EBIT (Operating Income) EBIT -30 -30
132% 132%
-
Net Profit -29 -29
126% 126%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aileron Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aileron Therapeutics, Inc. Stock News

Neutral
PRNewsWire
about one month ago
Announced promising safety and positive biomarker data from Cohort 2 (5mg BID) of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients demonstrating dose dependent effects in five biomarkers evaluated compared to low dose LTI-03 Data from Cohort 2 of the Phase 1b clinical trial confirms results from Cohort 1, with four biomarkers achieving statistical significan...
Neutral
PRNewsWire
about 2 months ago
High-dose LTI-03 (5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and decreased the expression of a biomarker indicative of epithelial health and lung function decline, suggesting potential therapeutic effect Positive trend observed in seven out of eight IPF biomarkers in Cohort 2, with four bioma...
Neutral
PRNewsWire
about 2 months ago
Agreement marks first of its kind for Advancium, a public charity launched by Deerfield Management and the Deerfield Foundation Advancium will evaluate ALRN-6924 as a potential therapy for retinoblastoma, a rare but devastating pediatric cancer of the eye AUSTIN, Texas and NEW YORK , Oct. 31, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company...
More Aileron Therapeutics, Inc. News

Company Profile

Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.

Head office United States
CEO Brian Windsor
Employees 15
Founded 2001
Website www.aileronrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today